Test: Favipiravir 200 mg (LOQULAR)
NOV2020/01925
Phase 1 small_molecule completed
Quick answer
Test: Favipiravir 200 mg (LOQULAR) for Bioequivalence is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BRIGHT MINDS BIOSCIENCES INC.
- Indication
- Bioequivalence
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed